<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555930</url>
  </required_header>
  <id_info>
    <org_study_id>14/LO/1574</org_study_id>
    <nct_id>NCT02555930</nct_id>
  </id_info>
  <brief_title>Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study</brief_title>
  <acronym>HIV-POGO</acronym>
  <official_title>Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to recruit a cohort of HIV patients with and without HIV-SN and to identify&#xD;
      genetic risk factors for the development of HIV-SN and neuropathic pain. It also aims to more&#xD;
      deeply phenotype the condition, using well validated questionnaires, and to identify any&#xD;
      influence that early neurocognitive dysfunction may have on the reporting, diagnosis and&#xD;
      treatment of neuropathic pain in the HIV population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV associated sensory neuropathy (HIV-SN) is a frequent complication of HIV infection,&#xD;
      affecting between 20 and 57% of infected individuals. The advent of better antiretroviral&#xD;
      treatment for HIV has meant that mortality from HIV has decreased dramatically in the UK.&#xD;
      This means however, that chronic, age-related conditions associated with HIV, such as HIV-SN&#xD;
      and cognitive impairment, are increasing in prevalence and becoming a significant disease&#xD;
      burden.&#xD;
&#xD;
      The classification, diagnosis and treatment of HIV-SN remains poor. Currently, little is&#xD;
      known about the genetic basis of the disorder and what risk factors mean that some patients&#xD;
      with HIV develop neuropathy and pain, whilst others do not. It is hoped that by further&#xD;
      characterising or 'phenotyping' the disorder, it will be easier to identify which patients&#xD;
      are at risk of developing neuropathy and chronic pain. It may also mean that treatment can be&#xD;
      more individualised as currently patients often undergo a frustrating 'trial and error'&#xD;
      protocol of treatment, as clinicians can not yet predict who will respond to which treatment.&#xD;
&#xD;
      It has also been suggested that there is a link between HIV-SN and HIV associated&#xD;
      neurocognitive disorder (HAND), which is another common, age-related complication of HIV&#xD;
      infection. It may be that the existence of one pathology could predict the development of the&#xD;
      other, or that the presence of HAND may impair the diagnosis or treatment of chronic pain&#xD;
      associated with HIV-SN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview</measure>
    <time_frame>Day 1</time_frame>
    <description>Doleur Neuropathique 4 Interview score greater than or equal to 4, indicating a high likelihood of neuropathic pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function: Global T-score for Cogstate Computerised Cognitive Function Test Set</measure>
    <time_frame>Day 1</time_frame>
    <description>Cogstate computerised cognitive function testing. A global T-score is a composite measure determined by the arithmetric mean of 8 test scores covering the following cognitive domains: psychomotor function, visual learning, working memory, executive function, emotional recognition, verbal learning, attention and verbal memory. Raw scores were converted to a standardised T score using age adjusted normative data (mean 50; standard deviation 10). Higher scores are interpreted as 'better' cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned Pain Modulation Efficiency</measure>
    <time_frame>Day 1</time_frame>
    <description>Conditioned Pain Modulation (CPM) efficiency to protocol using a cold noxious stimulus. The CPM efficiency is calculated as the pressure pain threshold (measured with an algometer on the forearm) during the noxious conditioning stimulus minus the pressure pain threshold prior to conditioning stimulus.</description>
  </secondary_outcome>
  <enrollment type="Actual">148</enrollment>
  <condition>HIV</condition>
  <condition>Sensory Neuropathy</condition>
  <condition>Neuropathic Pain</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No intervention - observational only</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals over the age of 18 of any gender with HIV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or over&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  co-incident severe neurological disease&#xD;
&#xD;
          -  co-incident severe psychiatric illness&#xD;
&#xD;
          -  limited english language skills so as not able to conduct quantitative sensory testing&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  pain of greater than 3/10 on an NRS due to pathology other than HIV-SN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew SC Rice, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pain Research Group, Dept Surgery &amp; Cancer, Imperial College, Chelsea and Westminster Campus</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Sensory Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02555930/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>NA all recruited were included</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Cohort</title>
          <description>Observational study whole cohort - Adults with HIV infection (with or without sensory neuropathy and/or neuropathic pain)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants recruited are included</population>
      <group_list>
        <group group_id="B1">
          <title>Total Cohort</title>
          <description>Observational study whole cohort - Adults with HIV infection (with or without sensory neuropathy or neuropathic pain)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not working through illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview</title>
        <description>Doleur Neuropathique 4 Interview score greater than or equal to 4, indicating a high likelihood of neuropathic pain</description>
        <time_frame>Day 1</time_frame>
        <population>Adults with HIV infection</population>
        <group_list>
          <group group_id="O1">
            <title>Total Cohort</title>
            <description>Whole cohort - Adults with HIV infection</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview</title>
          <description>Doleur Neuropathique 4 Interview score greater than or equal to 4, indicating a high likelihood of neuropathic pain</description>
          <population>Adults with HIV infection</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DN4 &gt;3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DN4 &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function: Global T-score for Cogstate Computerised Cognitive Function Test Set</title>
        <description>Cogstate computerised cognitive function testing. A global T-score is a composite measure determined by the arithmetric mean of 8 test scores covering the following cognitive domains: psychomotor function, visual learning, working memory, executive function, emotional recognition, verbal learning, attention and verbal memory. Raw scores were converted to a standardised T score using age adjusted normative data (mean 50; standard deviation 10). Higher scores are interpreted as 'better' cognitive function.</description>
        <time_frame>Day 1</time_frame>
        <population>All participants that completed Cogstate cognitive function testing</population>
        <group_list>
          <group group_id="O1">
            <title>Total Cohort</title>
            <description>Observational study whole cohort - Adults with HIV infection (with or without sensory neuropathy and/or neuropathic pain)</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function: Global T-score for Cogstate Computerised Cognitive Function Test Set</title>
          <description>Cogstate computerised cognitive function testing. A global T-score is a composite measure determined by the arithmetric mean of 8 test scores covering the following cognitive domains: psychomotor function, visual learning, working memory, executive function, emotional recognition, verbal learning, attention and verbal memory. Raw scores were converted to a standardised T score using age adjusted normative data (mean 50; standard deviation 10). Higher scores are interpreted as 'better' cognitive function.</description>
          <population>All participants that completed Cogstate cognitive function testing</population>
          <units>T-score for global measure of function</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.09" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conditioned Pain Modulation Efficiency</title>
        <description>Conditioned Pain Modulation (CPM) efficiency to protocol using a cold noxious stimulus. The CPM efficiency is calculated as the pressure pain threshold (measured with an algometer on the forearm) during the noxious conditioning stimulus minus the pressure pain threshold prior to conditioning stimulus.</description>
        <time_frame>Day 1</time_frame>
        <population>All subjects who completed full Conditioned Pain Modulation protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Cohort</title>
            <description>Observational study whole cohort - Adults with HIV infection (with or without sensory neuropathy and/or neuropathic pain)</description>
          </group>
        </group_list>
        <measure>
          <title>Conditioned Pain Modulation Efficiency</title>
          <description>Conditioned Pain Modulation (CPM) efficiency to protocol using a cold noxious stimulus. The CPM efficiency is calculated as the pressure pain threshold (measured with an algometer on the forearm) during the noxious conditioning stimulus minus the pressure pain threshold prior to conditioning stimulus.</description>
          <population>All subjects who completed full Conditioned Pain Modulation protocol</population>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse data was recorded for the 24 hours following the single clinical appointment for this observational study - the study did not involve an intervention and the only invasive procedure was a venous blood sample</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total Cohort</title>
          <description>Observational study whole cohort</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Harriet Kemp</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 20 3315 8816</phone>
      <email>h.kemp@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

